Delta-9-Tetrahydrocannabinol (THC): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Delta-9-tetrahydrocannabinol (THC) is a cannabinoid found in cannabis (Cannabis sativa). The psychoactive effects of cannabis are mainly due to THC.

There are over 80 cannabinoids in Cannabis sativa, but THC and cannabidiol (CBD) are the most well-studied. THC works by binding to specific sites in the brain and on the nerves. It's found in the highest levels in the leaves and flowers of the plant.

THC is commonly used as a recreational drug. People also use THC for multiple sclerosis (MS), nerve pain, nausea and vomiting from chemotherapy, alcohol use disorder, and many other conditions, but there is no good scientific evidence to support these uses. There is also no good evidence to support using THC for COVID-19.

Don't confuse THC with other cannabinoids found in cannabis, including cannabichromene (CBC), cannabidiol (CBD), cannabidivarin (CBDV), cannabigerol (CBG), cannabinol (CBN), delta-8-tetrahydrocannabinol (Delta-8-THC), or tetrahydrocannabivarin (THCV). Also don't confuse it with synthetic cannabinoids such as K2/Spice, or with plants containing THC, such as cannabis or hemp. These are not the same. THC is illegal on the federal level in the US. Due to its THC content, cannabis is classified as a Schedule I controlled substance. But some states have legalized or decriminalized recreational use.

Uses & Effectiveness

We currently have no information for Delta-9-Tetrahydrocannabinol (THC) overview.

Side Effects

When taken by mouth: THC is possibly unsafe when used in large amounts or long-term. Edible cannabis containing 50 mg or more of THC has been linked with serious side effects. Regularly taking large amounts of THC might cause cannabinoid hyperemesis syndrome (CHS). CHS leads to severe nausea and vomiting that doesn't respond to typical anti-nausea drugs. Also, using THC for at least 1-2 weeks can cause dependence.

When applied to the skin: A specific cannabis extract spray that contains THC and cannabidiol (Sativex, GW Pharmaceuticals) is possibly safe when used for up to 2 years. This product is a prescription drug in the UK and Canada. It is an investigation drug in the US.

When inhaled: THC is possibly unsafe when used in large amounts or long-term. Smoking or vaping THC can cause breathing problems. Vaping products containing THC have been linked to serious lung injury. Regularly smoking cannabis containing THC may cause CHS and/or dependence.

Special Precautions and Warnings

Pregnancy: Using THC is unsafe during pregnancy. The chemicals in cannabis, including THC, pass through the placenta and can slow the growth of the fetus and increase the risk for premature birth, stillbirth, childhood leukemia, abnormalities, or the need for intensive care after birth. It can also lead to lower intelligence and emotional problems in the child when they grow up. It also increases the risk for anemia and high blood pressure while pregnant.

Breast-feeding: Using THC is likely unsafe while breast-feeding. THC passes into breastmilk and stays in breastmilk for longer than 6 weeks, even after THC use has been stopped. This might slow down the development of the baby. Avoid all THC use if planning to breastfeed.

Bipolar disorder: Using THC might make manic symptoms worse in people with bipolar disorder.

Heart disease: THC might cause fast heartbeat and high blood pressure. It might also increase the risk of having a heart attack.

Epilepsy: High doses of THC might cause seizures in people with epilepsy. There have been several reports where high doses of cannabis that contains THC have caused seizures.

Schizophrenia: Using THC might make symptoms of schizophrenia worse.

Surgery: THC affects the central nervous system. It might slow the central nervous system too much when combined with anesthesia and other medications during and after surgery. Stop using THC at least 2 weeks before a scheduled surgery.

Interactions

Moderate Interaction

Be cautious with this combination

Medications moved by pumps in cells (P-glycoprotein Substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)
Some medications are moved in and out of cells by pumps. THC might change how these pumps work and change how much medication stays in the body. In some cases, this might change the effects and side effects of a medication.
Medications that decrease the breakdown of other medications by the liver (Cytochrome P450 2C9 (CYP2C9) inhibitors) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down THC. This could change the effects and side effects of THC.
Medications that decrease the breakdown of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down THC. This could change the effects and side effects of THC.
Medications that increase breakdown of other medications by the liver (Cytochrome P450 3A4 (CYP3A4) inducers) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC is changed and broken down by the liver. Some drugs increase how quickly the liver changes and breaks down THC. This could change the effects and side effects of THC.
Medications that increase the breakdown of other medications by the liver (Cytochrome P450 2C9 (CYP2C9) inducers) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC is changed and broken down by the liver. Some drugs increase how quickly the liver changes and breaks down THC. This could change the effects and side effects of THC.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC might slow blood clotting. Taking THC along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
Sedative medications (Barbiturates) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC might cause sleepiness and slowed breathing. Some medications, called sedatives, can also cause sleepiness and slowed breathing. Taking THC with sedative medications might cause breathing problems and/or too much sleepiness.
Sedative medications (CNS depressants) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC might cause sleepiness and slowed breathing. Some medications, called sedatives, can also cause sleepiness and slowed breathing. Taking THC with sedative medications might cause breathing problems and/or too much sleepiness.
Theophylline interacts with Delta-9-Tetrahydrocannabinol (THC)
Taking THC might decrease the effects of theophylline. But there isn't enough information to know if this is a big concern.
Warfarin (Coumadin) interacts with Delta-9-Tetrahydrocannabinol (THC)
Using THC might increase the effects of warfarin. Smoking THC while taking warfarin might increase the chance of bruising and bleeding.
Alcohol interacts with Delta-9-Tetrahydrocannabinol (THC)
Using THC with alcohol might increase the effects of alcohol on the central nervous system. This might increase the risk for some side effects, such as drowsiness and mood changes.
Anesthesia interacts with Delta-9-Tetrahydrocannabinol (THC)
Using THC might increase how much anesthesia your doctor needs to give to you for surgery. Tell your doctor if you regularly use THC or cannabis. If possible, stop using THC at least 2 weeks before surgery.
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)
Some medications are changed and broken down by the liver. THC might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)
Some medications are changed and broken down by the liver. THC might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)
Some medications are changed and broken down by the liver. THC might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications for dissolving blood clots (Thrombolytic drugs) interacts with Delta-9-Tetrahydrocannabinol (THC)
THC might slow blood clotting. Taking THC with medications used for dissolving blood clots might increase the chance of bleeding and bruising.

Dosing

THC is commonly used in capsules, edible products, sprays, vape products, and cigarettes. The effects and side effects of THC products can vary significantly depending on how much THC they contain. Concentrations range from 1% to 80% THC. Speak with a healthcare provider to find out what type of product and dose might be best for a specific condition.

THC is illegal under federal law in the US. Due to its THC content, cannabis is classified as a Schedule I controlled substance. Some states have legalized or decriminalized use.

View References

REFERENCES:

The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.

Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and Pharmacobiotechnology. Baltimore, MD: Williams & Wilkins, 1996.

Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.

Hebel SK, ed. Drug Facts and Comparisons. 52nd ed. St. Louis: Facts and Comparisons, 1998.

Tyrey L. Delta 9-Tetrahydrocannabinol: a potent inhibitor of episodic luteinizing hormone secretion. J Pharmacol Exp Ther 1980;213:306-8.

Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.

Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Medicine 2000;6:313-9.

Piomelli D. Pot of gold for glioma therapy. Nat Med 2000;6:255-6.

Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-7.

Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions: 2000. J Am Board Fam Pract 2000;13:274-98.

Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000;164:6461-6..

Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000;165:373-80..

Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21..

Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97..

Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-8..

Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26..

Marinol Prescribing Information. Solvay Pharmaceuticals, Rev March 2008. Available at: https://www.solvaypharmaceuticals-us.com/static/wma/pdf/1/3/2/5/0/004InsertText500012RevMar2008.pdf (Accessed 2 July 2009).

Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 2009;43:1347-53.

Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:e694-e701.

Pellinen, P., Honkakoski, P., Stenback, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M. A., and Pasanen, M. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur.J Pharmacol 1-3-1994;270(1):35-43.

Johnson, E. M. Substance abuse and women's health. Public Health Rep. 1987;102(4 Suppl):42-48.

Astley, S. J. and Little, R. E. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol.Teratol. 1990;12(2):161-168.

Levy, R., Schurr, A., Nathan, I., Dvilanski, A., and Livne, A. Impairment of ADP-induced platelet aggregation by hashish components. Thromb.Haemost. 12-31-1976;36(3):634-640.

Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., and James, I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92(1-2):91-100.

Darmani, N. A. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. J Pharmacol Exp.Ther. 2002;300(1):34-42.

Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS.Drugs 2003;17(3):179-202.

Sheweita, S. A. Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. Toxicology 9-30-2003;191(2-3):133-142.

Fox, P., Bain, P. G., Glickman, S., Carroll, C., and Zajicek, J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 4-13-2004;62(7):1105-1109.

Grotenhermen, F. Pharmacology of cannabinoids. Neuro.Endocrinol.Lett. 2004;25(1-2):14-23.

Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M., and Reif, M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult.Scler. 2004;10(4):417-424.

Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819.

Blake, D. R., Robson, P., Ho, M., Jubb, R. W., and McCabe, C. S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology.(Oxford) 2006;45(1):50-52.

Perras, C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg.Health Technol. 2005;(72):1-4.

Zhu, H. J., Wang, J. S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., and Devane, C. L. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp.Ther. 2006;317(2):850-857.

Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., and Arnold, J. C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem.Pharmacol 4-14-2006;71(8):1146-1154.

Barnes, M. P. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert.Opin.Pharmacother. 2006;7(5):607-615.

Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y. D., Schnelle, M., Reif, M., and Cerny, T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 7-20-2006;24(21):3394-3400.

Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., and Robson, P. J. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-353.

Levitt, D. G. Heterogeneity of human adipose blood flow. BMC.Clin Pharmacol 2007;7:1.

Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., and Petersen, K. L. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2-13-2007;68(7):515-521.

Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., Rubino, T., Michalski, C. W., Marsicano, G., Monory, K., Mackie, K., Marian, C., Batkai, S., Parolaro, D., Fischer, M. J., Reeh, P., Kunos, G., Kress, M., Lutz, B., Woolf, C. J., and Kuner, R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat.Neurosci. 2007;10(7):870-879.

Rog, D. J., Nurmikko, T. J., and Young, C. A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079.

Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., and Fishman, S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J.Pain 2008;9(6):506-521.

Cappelli, F., Lazzeri, C., Gensini, G. F., and Valente, S. Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc.Med.(Hagerstown.) 2008;9(7):725-728.

Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., and Atkinson, J. H. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34(3):672-680.

Reece, A. S. Chronic toxicology of cannabis. Clin Toxicol.(Phila) 2009;47(6):517-524.

Nawrot, T. S., Perez, L., Kunzli, N., Munters, E., and Nemery, B. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet 2-26-2011;377(9767):732-740.

Lynch, M. E. and Campbell, F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br.J.Clin.Pharmacol. 2011;72(5):735-744.

Li, M. C., Brady, J. E., DiMaggio, C. J., Lusardi, A. R., Tzong, K. Y., and Li, G. Marijuana use and motor vehicle crashes. Epidemiol.Rev. 2012;34(1):65-72.

Richards, B. L., Whittle, S. L., and Buchbinder, R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane.Database.Syst.Rev. 2012;1:CD008921.

Asbridge, M., Hayden, J. A., and Cartwright, J. L. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.

Formukong, E. A., Evans, A. T., and Evans, F. J. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J.Pharm.Pharmacol. 1989;41(10):705-709.

Hollister, L. E. Interactions of cannabis with other drugs in man. NIDA Res.Monogr 1986;68:110-116.

Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92.

Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421-9.

Overview. GW Pharmaceuticals Web site. Available at: https://www.gwpharm.com/about-us-overview.aspx. Accessed: May 31, 2015.

Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28.

Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260(1):285-95.

Guy GW, Stott CG. "The development of Sativex - a natural cannabis-based medicine." Ed. R Mechoulam. Cannabinoids as Therapeutics. Basel, Switzerland: Birkhauser Verlag, 2005. 231-263.

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-9.

Gibbs M, Winsper C, Marwaha S, et al. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39-47.

Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the Field: Death Following Ingestion of an Edible Marijuana Product--Colorado, March 2014. MMWR Morb Mortal Wkly Rep. 2015;64(28):771-2.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125-32.

Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330(7481):11.

Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19(2):187-94.

Huson HB, Granados TM, Rasko Y. Surgical considerations of marijuana use in elective procedures. Heliyon. 2018;4(9):e00779.

Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017;9(7):2079-2092.

Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986.

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-9.

Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456-73.

Zorrilla I, Aguado J, Haro JM, et al. Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand. 2015;131(2):100-10.

Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.e1.

Shere A, Goyal H. Cannabis can augment thrombolytic properties of rtPA: Intracranial hemorrhage in a heavy cannabis user. Am J Emerg Med. 2017;35(12):1988.e1-1988.e2.

Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-63.

Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37.

Cadman PE. Hypophosphatemia in Users of Cannabis. Am J Kidney Dis. 2017;69(1):152-155.

Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019;124(1):28-31.

Fogang YF, Camara M, Mbonda PC, Toffa D, Touré K. Late onset epilepsy associated with marijuana abuse: a case report with MRI findings. Pan Afr Med J. 2014;17:158.

Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid Hyperemesis Syndrome: Reports of Fatal Cases. J Forensic Sci. 2019;64(1):270-274.

Toce MS, Farias M, Powell AJ, Daly KP, Vargas SO, Burns MM. Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy. Pediatr Dev Pathol. 2019;22(1):80-86.

Agriculture Improvement Act, S. 10113, 115th Cong. (2018) or S. 12619, 115th Cong. (2018).

Statement from FDA Commissioner Scot Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency's regulation of products containing cannabis and cannabis-derived compounds. U.S. Food and Drug Administration Web site. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Accessed May 7, 2019).

Product information for Marinol. AbbVie. North Chicago, IL 60064. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.

van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019 Apr;160(4):860-869.

Lewis N, McCaffrey K, Sage K, et al. E-cigarette Use, or Vaping, Practices and Characteristics Among Persons with Associated Lung Injury - Utah, April-October 2019. MMWR Morb Mortal Wkly Rep. 2019 Oct 25;68(42):953-956.

Chocron Y, Zuber JP, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ. 2019 Jul 19;366:l4336.

Kheifets M, Karniel E, Landa D, Vons SA, Meridor K, Charach G. Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case Series. Isr Med Assoc J. 2019 Jun;21(6):404-407.

Corsi DJ, Walsh L, Weiss D, et al. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA. 2019 Jul 9;322(2):145-152.

Spindle TR, Cone EJ, Schlienz NJ, et al. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. J Anal Toxicol. 2019 May 1;43(4):233-258.

FDA Consumer Updates: Vaping Illness Update: FDA Warns Public to Stop Using Tetrahydrocannabinol (THC)-Containing Vaping Products and Any Vaping Products Obtained Off the Street. U.S. Food and Drug Administration (FDA). October 2019. Available at: https://www.fda.gov/consumers/consumer-updates/vaping-illness-update-fda-warns-public-stop-using-tetrahydrocannabinol-thc-containing-vaping.

Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019 Nov 1;2(11):e1916318.

Rodriguez CE, Sheeder J, Allshouse AA, et al. Marijuana use in young mothers and adverse pregnancy outcomes: a retrospective cohort study. BJOG. 2019 Nov;126(12):1491-1497.

Smid MC. Marijuana use among young pregnant women: more common and more harmful than we think. BJOG. 2019 Nov;126(12):1498.

Brar BK, Patil PS, Jackson DN, Gardner MO, Alexander JM, Doyle NM. Effect of intrauterine marijuana exposure on fetal growth patterns and placental vascular resistance. J Matern Fetal Neonatal Med. 2019 Nov 11:1-5.

Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007 Aug; 4(8):1770-1804.

Budney AJ, Roffman R, Stephens R, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4-16.

Zehra A, Burns J, Liu CK, et al. Cannabis Addiction and the Brain: a Review. J Neuroimmune Pharmacol. 2018;13(4):438-52.

Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(4):e202370.

Anees B, Meyyappan AC, Hawken ER. Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis. Can J Psychiatry. 2020;65(6):365-376.

Hacke ACM, Lima D, de Costa F, et al. Probing the antioxidant activity of [delta](9)-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst. 2019;144(16):4952-4961.

Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95(14):8268-73.

Santaella-Tenorio J, Wheeler-Martin K, DiMaggio CJ, et al. Association of Recreational Cannabis Laws in Colorado and Washington State With Changes in Traffic Fatalities, 2005-2017. JAMA Intern Med. 2020.

Kloft L, Otgaar H, Blokland A, Garbaciak A, Monds LA, Ramaekers JG. False memory formation in cannabis users: a field study. Psychopharmacology (Berl). 2019;236(12):3439-3450.

Rosekind MR, Ehsani JP, Michael JP. Reducing Impaired Driving Fatalities: Data Need to Drive Testing, Enforcement, and Policy. JAMA Intern Med. 2020.

Kamer RS, Warshafsky S, Kamer GC. Change in Traffic Fatality Rates in the First 4 States to Legalize Recreational Marijuana. JAMA Intern Med. 2020.

Paul SP, Hatoum AS, Fine JD, et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD Study. JAMA Psychiatry. 2020;e202902.

Ammerman SD, Ryan SA, Adelman WP, et al. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3):584-7.

Emoto J, Weeks K, Kallail KJ. Accidental Acute Cannabis Intoxication Presenting as Seizure in Pediatrics Patients. Kans J Med. 2020;13: 129-130.

Monte AA, K Shelton SK, Mills E., Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med. 2019 Apr 16;170(8):531-537.

Abuhasira R, Haviv YS, Leiba M, Leiba A, Ryvo L, Novack V. Cannabis is associated with blood pressure reduction in older adults - A 24-hours ambulatory blood pressure monitoring study. Eur J Intern Med. 2021:S0953-6205(21)00005-4.

Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24(8):1505-1516.

Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and ?9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020;324(21):2177-2186.

Brown GW, Bellnier TJ, Janda M, Miskowitz K. ?-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. J Am Pharm Assoc (2003). 2021;61(1):e57-e60.

Cole TB, Saitz R. Cannabis and Impaired Driving. JAMA. 2020;324(21):2163-2164.

Corsi DJ, Donelle J, Sucha E, et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat Med. 2020;26(10):1536-1540.

Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553-1560.

Grzeskowiak LE, Grieger JA, Andraweera P, et al. The deleterious effects of cannabis during pregnancy on neonatal outcomes. Med J Aust. 2020;212(11):519-524.

Schindler EAD, Schnakenberg Martin AM, Sewell RA, et al. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology (Berl). 2020;237(10):3097-3107.

Spindle TR, Cone EJ, Herrmann ES, et al. Pharmacokinetics of Cannabis Brownies: A Controlled Examination of ?9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females. J Anal Toxicol. 2020;44(7):661-671.

Tournier N, Lucie Chevillard L, Megarbane B, et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13(7):905-15.

Arnold JC, Hone P, Holland ML, Allen JD. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep. 2012;64(3):751-7.

Wymore EM, Palmer C, Wang GS, et al. Persistence of ?-9-Tetrahydrocannabinol in Human Breast Milk JAMA Pediatr. 2021. doi: 10.1001/jamapediatrics.2020.6098.

Torres-Moreno MC, Papaseit E, Torrens M, Farré M. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1(6):e183485.

Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524.

Mullins MF. Cannabis dabbing: An emerging trend. Nursing. 2021;51(5):46-50.

Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245-50.

Kimura T, Takaya M, Usami N, Watanabe K, Yamamoto I. ?9-Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB1 receptor. Forensic Toxicol. 2019;37(1):207-214.

Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482.

Poyatos L, Pérez-Acevedo AP, Papaseit E, et al. Oral administration of Cannabis and ?-9-tetrahydrocannabinol (THC) preparations: A systematic review. Medicina (Kaunas). 2020;56(6):309.

Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ 2021;374:n1034.

Noori A, Miroshnychenko A, Shergill Y, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open 2021;11(7):e047717.

Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep 2021;44(11):zsab149.

Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial. J Crohns Colitis 2021;15(11):1799-1806.

Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS One 2021;16(2):e0246871.

Urbi B, Corbett J, Hughes I, et al. Effects of Cannabis in Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis 2022;12(2):495-508.

Kasuda S, Kondo T, Terazawa I, Morimoto M, Yuui K, Kudo R. Cardiac sudden death in a young cannabis user. Leg Med (Tokyo) 2021;53:101955.

Shah VD, Mohammad A, Nandkeolyar S, Stoletniy L, Contractor T. Torsades de Pointes due to Excessive Marijuana Use in a Susceptible Patient. Case Rep Cardiol 2021;2021:6621496.

Zloto O, Weisman A, Avisar I, et al. Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study. Graefes Arch Clin Exp Ophthalmol 2022;260(5):1707-1712.

Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ 2021;374:n2040.

Marchand G, Masoud AT, Govindan M, et al. Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5(1):e2145653.

Berl V, Hurd YL, Lipshutz BH, Roggen M, Mathur EJ, Evans M. A randomized, triple-blind, comparator-controlled parallel study investigating the pharmacokinetics of cannabidiol and tetrahydrocannabinol in a novel delivery system, Solutech, in association with cannabis use history. Cannabis Cannabinoid Res 2022.

US Drug Enforcement Agency (DEA). Cannabis. 2021. Available at: https://museum.dea.gov/exhibits/online-exhibits/cannabis-coca-and-poppy-natures-addictive-plants/cannabis.

Gedin F, Blomé S, Pontén M, et al. Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: A systematic review and meta-analysis. JAMA Netw Open 2022;5(11):e2243848.

Maharaj N, Swarath S, Seecheran R, Seecheran V, Seecheran NA. Suspected cannabis vaping-induced pericardial effusion. J Investig Med High Impact Case Rep 2022;10:23247096221140251.

Idris I, Diez JR, Assoku BA, Beker S. Accidental ingestion of tetrahydrocannabinol-laced gummies causing bradycardia and first-degree atrioventricular block in a pediatric patient: A case report. Cureus 2022;14(7):e26826.

Senderovich H, Waicus S. A case report on cannabinoid hyperemesis syndrome in palliative care: How good intentions can go wrong. Oncol Res Treat 2022;45(7-8):438-443.

Englund A, Oliver D, Chesney E, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology 2022.

Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain 2022.

Murray CH, Glazer JE, Lee R, Nusslock R, de Wit H. ?9-THC reduces reward-related brain activity in healthy adults. Psychopharmacology (Berl) 2022;239(9):2829-2840.

Hutten NRPW, Arkell TR, Vinckenbosch F, et al. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis. Psychopharmacology (Berl) 2022;239(11):3731-3741.

Ray CL, Bylo MP, Pescaglia J, Gawenis JA, Greenlief CM. Delta-8 tetrahydrocannabinol product impurities. Molecules 2022;27(20):6924.

Chester LA, Englund A, Chesney E, et al. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study. Cannabis Cannabinoid Res 2022.

Pisani S, McGoohan K, Velayudhan L, Bhattacharyya S. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 2021;38(10):887-910.

Highlights of prescribing information. MARINOL (dronabinol) capsules, for oral use, CIII. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed April 10, 2023.

Cesamet (nabilone) capsules for oral administration. May 2006. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed April 10, 2023.

Bell AD, MacCallum C, Margolese S, et al. Clinical Practice Guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions. Cannabis Cannabinoid Res. 2023.

Moussa MK, Hall MAK, Akwe J. Cannabis-induced acute encephalopathy in a 94-year-old woman due to family administration of cannabidiol (CBD) products: A case report. Cureus 2023;15(4):e37927.

Zamarripa CA, Spindle TR, Surujunarain R, et al. Assessment of orally administered ?9-tetrahydrocannabinol when coadministered with cannabidiol on ?9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: A randomized clinical trial. JAMA Netw Open 2023;6(2):e2254752.

Häuser W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA. Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database Syst Rev 2023;6(6):CD014915.

van Dam CJ, van der Schrier R, van Velzen M, et al. Inhaled Delta(9)-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers. Br J Anaesth 2023;130(4):485-493.

Treyer A, Reinhardt JK, Eigenmann DE, Oufir M, Hamburger M. Phytochemical comparison of medicinal cannabis extracts and study of their CYP-mediated interactions with coumarinic oral anticoagulants. Med Cannabis Cannabinoids. 2023;6(1):21-31.

Patel PA, Sanborn E, Then R, Williams DM. Recurrent Reversible Cerebral Vasoconstriction Syndrome: A Report of Two Cases. Cureus 2023;15(8):e42992.

Kleiner D, Horváth IL, Bunduc S, Gergo D, Lugosi K, Fehérvári P, Hegyi P, Csupor D. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. Curr Neuropharmacol. 2023;21(12):2505-2515.

Bansal S, Zamarripa CA, Spindle TR, et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther 2023.

Afshar S, Khalili S, Amin G, Abbasinazari M. A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients. Iran J Pharm Res 2023;21(1):e132647.

U.S. Department of Health and Human Services. August 2023. Available at: https://www.dropbox.com/scl/fi/pw3rfs9gm6lg80ij9tja6/2023-01171-Supplemental-Release-1.pdf?rlkey=v5atj0tcnhxhnszyyzcwdcvvt&dl=0. Accessed April 3, 2024.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.

Delta-9-Tetrahydrocannabinol (THC) - Uses, Side Effects, and More

Overview

Uses & Effectiveness

Side Effects

Special Precautions and Warnings

Interactions

Moderate Interaction

Medications moved by pumps in cells (P-glycoprotein Substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications that decrease the breakdown of other medications by the liver (Cytochrome P450 2C9 (CYP2C9) inhibitors) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications that decrease the breakdown of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications that increase breakdown of other medications by the liver (Cytochrome P450 3A4 (CYP3A4) inducers) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications that increase the breakdown of other medications by the liver (Cytochrome P450 2C9 (CYP2C9) inducers) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with Delta-9-Tetrahydrocannabinol (THC)

Sedative medications (Barbiturates) interacts with Delta-9-Tetrahydrocannabinol (THC)

Sedative medications (CNS depressants) interacts with Delta-9-Tetrahydrocannabinol (THC)

Theophylline interacts with Delta-9-Tetrahydrocannabinol (THC)

Warfarin (Coumadin) interacts with Delta-9-Tetrahydrocannabinol (THC)

Alcohol interacts with Delta-9-Tetrahydrocannabinol (THC)

Anesthesia interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with Delta-9-Tetrahydrocannabinol (THC)

Medications for dissolving blood clots (Thrombolytic drugs) interacts with Delta-9-Tetrahydrocannabinol (THC)

Dosing